Caprion Collaborating With FNIH to Test Alzheimer's Protein Panel

Aug 24, 2017

|

Premium

NEW YORK (GenomeWeb) – Caprion Bioscience is investigating whether a five-protein panel can be useful in early detection and predicting progression in Alzheimer's disease.

The company said this week that it has entered in a collaboration with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to measures proteins in its CNS ProteoCarta MRM biomarker panel in longitudinally collected samples from some 200 subjects from the Alzheimer's Disease Neuroimaging initiative.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

95-plex Immune Cell Phenotyping Assay

Oct

10

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Ask the Experts: Ensuring High-Quality Proteomic Studies with Core Lab Resources

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.

Main menu